What is ADCETRIS 50mg
ADCETRIS 50 mg is a sterile, lyophilized powder for intravenous infusion containing Brentuximab vedotin, an antibody-drug conjugate (ADC) targeting CD30-expressing cells. It's primarily prescribed for adults to treat:
- Classical Hodgkin Lymphoma (cHL): After failure of autologous stem cell transplant or at least two prior multi-agent chemotherapy regimens.
- Systemic Anaplastic Large Cell Lymphoma (sALCL): After failure of at least one prior multi-agent chemotherapy regimen.
- Peripheral T-cell Lymphoma (PTCL): In combination with chemotherapy for previously untreated patients.
- Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or CD30-expressing Mycosis Fungoides (MF): After prior systemic therapy.
Brentuximab vedotin combines a monoclonal antibody specific for CD30 with the microtubule-disrupting agent monomethyl auristatin E (MMAE), delivering targeted cytotoxicity to malignant cells.
How to use ADCETRIS 50mg
Administration Guidelines:
- Preparation: Reconstitute each 50 mg vial with 10.5 mL of sterile water for injection to yield a 5 mg/mL solution. Further dilute in 100–150 mL of 0.9% sodium chloride or 5% dextrose solution.
- Infusion: Administer as a 30-minute intravenous infusion. Do not administer as an intravenous push or bolus.
- Dosage: Typically, 1.8 mg/kg every 3 weeks. Adjustments may be necessary based on individual patient factors.
- Monitoring: Observe patients during and after infusion for signs of hypersensitivity or infusion-related reactions.
Always follow institutional guidelines and consult the full prescribing information for detailed preparation and administration instructions.
Mode of Action ADCETRIS 50mg
Pharmacodynamics:
- Targeting CD30: The monoclonal antibody component binds specifically to the CD30 antigen on the surface of malignant cells.
- Internalization and Release: Upon binding, the ADC-CD30 complex is internalized, and MMAE is released into the cytoplasm.
- Microtubule Disruption: MMAE binds to tubulin, disrupting the microtubule network, leading to cell cycle arrest and apoptosis.
This targeted approach allows for the selective destruction of CD30-expressing malignant cells while minimizing damage to normal tissues.
ADCETRIS 50mg Interactions ADCETRIS 50mg
Drug Interactions:
- CYP3A4 Inhibitors: Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase MMAE exposure, enhancing toxicity. Monitor patients closely.
- CYP3A4 Inducers: Concurrent use with CYP3A4 inducers (e.g., rifampin) may decrease MMAE exposure, potentially reducing efficacy.
- Bleomycin: Concomitant use is contraindicated due to increased risk of pulmonary toxicity.
- Alcohol: May exacerbate hepatotoxic effects; advise patients to limit or avoid alcohol consumption during treatment.
Always review the patient's medication profile for potential interactions before initiating ADCETRIS therapy.
Dosage of ADCETRIS 50mg
Recommended Dosages:
- Monotherapy: 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks.
- Combination Therapy: In combination with chemotherapy agents, the dosage may vary. Refer to specific protocols for guidance.
- Dose Adjustments: Modify dosage in patients with hepatic or renal impairment, or in response to adverse reactions such as peripheral neuropathy or hematologic toxicity.
Dosage should be individualized based on patient weight, treatment regimen, and tolerability. Consult the prescribing information for detailed dosing guidelines.
Possible side effects of ADCETRIS 50mg
Common Side Effects:
- Peripheral neuropathy
- Fatigue
- Nausea
- Diarrhea
- Neutropenia
- Upper respiratory tract infection
- Pyrexia
- Constipation
- Vomiting
- Alopecia
- Decreased appetite
Serious Side Effects:
- Progressive multifocal leukoencephalopathy (PML)
- Hepatotoxicity
- Infusion-related reactions
- Stevens-Johnson syndrome
- Tumor lysis syndrome
Patients should be monitored regularly for signs of adverse reactions, and appropriate interventions should be implemented as necessary.
ADCETRIS 50mg Contraindications ADCETRIS 50mg
Contraindicated Conditions:
- Concomitant Bleomycin Use: Due to increased risk of pulmonary toxicity, the combination of ADCETRIS with bleomycin is contraindicated.
- Hypersensitivity: Patients with known hypersensitivity to brentuximab vedotin or any of its components should not receive ADCETRIS.
Assess patient history thoroughly to identify any contraindications before initiating therapy.
Storage of ADCETRIS 50mg
Storage Instructions:
- Unreconstituted Vials: Store at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.
- Reconstituted Solution: If not used immediately, may be stored at 2°C to 8°C for up to 24 hours. Do not freeze.
- Diluted Infusion Solution: Should be administered immediately. If not used promptly, may be stored at 2°C to 8°C for up to 24 hours. Do not freeze.
- Handling: ADCETRIS is a hazardous drug. Follow appropriate handling and disposal procedures in accordance with institutional guidelines.
Proper storage and handling are essential to maintain the stability and efficacy of ADCETRIS.
ADCETRIS 50mg features an exceptional active ingredient renowned for its potent effects, comprising Brentuximab vedotin. This powerful formulation provides a superior solution for addressing diverse health concerns. With 50mg/Vial concentration and an easily manageable Infusion/Powder for, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about ADCETRIS 50mg .
Welcome to Dwaey, specifically on ADCETRIS 50mg page.
This medicine contains an important and useful components, as it consists of Brentuximab vedotin.
ADCETRIS 50mg is available in the market in concentration 50mg/Vial and in the form of Infusion/Powder for.
TAKEDA PHARMA A/S is the producer of ADCETRIS 50mg and it is imported from DENMARK,
The most popular alternatives of ADCETRIS 50mg are listed downward .
-
Active Substance
-
Size
-
Indications
- No indications available.
-
Type
-
Company
Frequently Asked Questions
ADCETRIS 50mg should be stored according to the instructions provided by TAKEDA PHARMA A/S.
In general, it is recommended to store ADCETRIS 50mg in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with ADCETRIS 50mg may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking ADCETRIS 50mg for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking ADCETRIS 50mg . Some medications, including
ADCETRIS 50mg , may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of ADCETRIS 50mg , take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking ADCETRIS 50mg without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking ADCETRIS 50mg if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of ADCETRIS 50mg during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 50mg/Vial,
and the specific recommendations of TAKEDA PHARMA A/S.
The effects of ADCETRIS 50mg on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 50mg/Vial, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking ADCETRIS 50mg with or without food may vary depending on the medication
and the recommendations of TAKEDA PHARMA A/S. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of ADCETRIS 50mg in children or elderly individuals may depend on various factors, including
the specific medication, type Infusion/Powder for, and the recommendations of TAKEDA PHARMA A/S. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of ADCETRIS 50mg in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments